NeuroImmune pharmacology and therapeutics

Keyphrases

Publications

volume 3, number 1, 2024

Peter W Halcrow, Darius N K Quansah, Nirmal Kumar, Rebecca L Solloway, Kayla M Teigen, Kasumi A Lee, Braelyn Liang, Jonathan D Geiger
Weak base drug-induced endolysosome iron dyshomeostasis controls the generation of reactive oxygen species, mitochondrial depolarization, and cytotoxicity. NeuroImmune pharmacology and therapeutics 3 (1) (2024)
Sumita Raha, Ramesh K Paidi, Debashis Dutta, Kalipada Pahan
Cinnamic acid, a natural plant compound, exhibits neuroprotection in a mouse model of Sandhoff disease via PPARα. NeuroImmune pharmacology and therapeutics 3 (1) (2024)
Susanta Mondal, Shelby Prieto, Suresh B Rangasamy, Debashis Dutta, Kalipada Pahan
Nebulization of low-dose aspirin ameliorates Huntington's pathology in N171-82Q transgenic mice. NeuroImmune pharmacology and therapeutics 3 (1) (2024)
Sumita Raha, Ramesh K Paidi, Debashis Dutta, Kalipada Pahan
Cinnamic acid, a natural plant compound, exhibits neuroprotection in a mouse model of Sandhoff disease via PPARα. NeuroImmune pharmacology and therapeutics 3 (1) (2024)
Susanta Mondal, Shelby Prieto, Suresh B Rangasamy, Debashis Dutta, Kalipada Pahan
Nebulization of low-dose aspirin ameliorates Huntington's pathology in N171-82Q transgenic mice. NeuroImmune pharmacology and therapeutics 3 (1) (2024)
Michael Stangis, Daniel Adesse, Bhavya Sharma, Eduardo Castro, Kush Kumar, Neil Kumar, Masha Minevich, Michal Toborek
The S1 subunits of SARS-CoV-2 variants differentially trigger the IL-6 signaling pathway in human brain endothelial cells and downstream impact on microglia activation. NeuroImmune pharmacology and therapeutics 3 (1) (2024)
Peter W Halcrow, Darius N K Quansah, Nirmal Kumar, Rebecca L Solloway, Kayla M Teigen, Kasumi A Lee, Braelyn Liang, Jonathan D Geiger
Weak base drug-induced endolysosome iron dyshomeostasis controls the generation of reactive oxygen species, mitochondrial depolarization, and cytotoxicity. NeuroImmune pharmacology and therapeutics 3 (1) (2024)
Michael Stangis, Daniel Adesse, Bhavya Sharma, Eduardo Castro, Kush Kumar, Neil Kumar, Masha Minevich, Michal Toborek
The S1 subunits of SARS-CoV-2 variants differentially trigger the IL-6 signaling pathway in human brain endothelial cells and downstream impact on microglia activation. NeuroImmune pharmacology and therapeutics 3 (1) (2024)

volume 3, number 2, 2024

Jessica M Proulx, In-Woo Park, Kathleen Borgmann
HIV-1 and methamphetamine co-treatment in primary human astrocytes: TAARgeting ER/UPR dysfunction. NeuroImmune pharmacology and therapeutics 3 (2) (2024)
Miguel Perez-Pouchoulen, Amanda S Holley, Erin L Reinl, Jonathan W VanRyzin, Amir Mehrabani, Christie Dionisos, Muhammed Mirza, Margaret M McCarthy
Viral-mediated inflammation by Poly I:C induces the chemokine CCL5 in NK cells and its receptors CCR1 and CCR5 in microglia in the neonatal rat cerebellum. NeuroImmune pharmacology and therapeutics 3 (2) (2024)
Jessica M Proulx, In-Woo Park, Kathleen Borgmann
HIV-1 and methamphetamine co-treatment in primary human astrocytes: TAARgeting ER/UPR dysfunction. NeuroImmune pharmacology and therapeutics 3 (2) (2024)
Anna Elizabeth Laird, Alexandra Anh Le, Jacqueline R Kulbe, Anya Umlauf, Melody Sagarian, Matthew Spencer, Anish Sathe, David J Grelotti, Jennifer Iudicello, Brook Henry, Ronald J Ellis, Jerel Adam Fields
Sera from people with HIV and depression induce commensurate metabolic alterations in astrocytes: toward precision diagnoses and therapies. NeuroImmune pharmacology and therapeutics 3 (2) (2024)
Anna Elizabeth Laird, Alexandra Anh Le, Jacqueline R Kulbe, Anya Umlauf, Melody Sagarian, Matthew Spencer, Anish Sathe, David J Grelotti, Jennifer Iudicello, Brook Henry, Ronald J Ellis, Jerel Adam Fields
Sera from people with HIV and depression induce commensurate metabolic alterations in astrocytes: toward precision diagnoses and therapies. NeuroImmune pharmacology and therapeutics 3 (2) (2024)
Anna Elizabeth Laird, Alexandra Anh Le, Jacqueline R Kulbe, Anya Umlauf, Melody Sagarian, Matthew Spencer, Anish Sathe, David J Grelotti, Jennifer Iudicello, Brook Henry, Ronald J Ellis, Jerel Adam Fields
Sera from people with HIV and depression induce commensurate metabolic alterations in astrocytes: toward precision diagnoses and therapies. NeuroImmune pharmacology and therapeutics 3 (2) (2024)
Miguel Perez-Pouchoulen, Amanda S Holley, Erin L Reinl, Jonathan W VanRyzin, Amir Mehrabani, Christie Dionisos, Muhammed Mirza, Margaret M McCarthy
Viral-mediated inflammation by Poly I:C induces the chemokine CCL5 in NK cells and its receptors CCR1 and CCR5 in microglia in the neonatal rat cerebellum. NeuroImmune pharmacology and therapeutics 3 (2) (2024)
Jessica M Proulx, In-Woo Park, Kathleen Borgmann
HIV-1 and methamphetamine co-treatment in primary human astrocytes: TAARgeting ER/UPR dysfunction. NeuroImmune pharmacology and therapeutics 3 (2) (2024)
Miguel Perez-Pouchoulen, Amanda S Holley, Erin L Reinl, Jonathan W VanRyzin, Amir Mehrabani, Christie Dionisos, Muhammed Mirza, Margaret M McCarthy
Viral-mediated inflammation by Poly I:C induces the chemokine CCL5 in NK cells and its receptors CCR1 and CCR5 in microglia in the neonatal rat cerebellum. NeuroImmune pharmacology and therapeutics 3 (2) (2024)
Jessica M Proulx, In-Woo Park, Kathleen Borgmann
HIV-1 and methamphetamine co-treatment in primary human astrocytes: TAARgeting ER/UPR dysfunction. NeuroImmune pharmacology and therapeutics 3 (2) (2024)

volume 3, number 1, 2023

Haylee R Hammond, Shainnel O Eans, Thomas J Cirino, Subramaniam Ananthan, Ana Catya Jimenez-Torres, Jun Zhu, Jay P McLaughlin
SRI-30827, a novel allosteric modulator of the dopamine transporter, alleviates HIV-1 Tat-induced potentiation of cocaine conditioned place preference in mice. NeuroImmune pharmacology and therapeutics 3 (1) (2023)
Haylee R Hammond, Shainnel O Eans, Thomas J Cirino, Subramaniam Ananthan, Ana Catya Jimenez-Torres, Jun Zhu, Jay P McLaughlin
SRI-30827, a novel allosteric modulator of the dopamine transporter, alleviates HIV-1 Tat-induced potentiation of cocaine conditioned place preference in mice. NeuroImmune pharmacology and therapeutics 3 (1) (2023)
Haylee R Hammond, Shainnel O Eans, Thomas J Cirino, Subramaniam Ananthan, Ana Catya Jimenez-Torres, Jun Zhu, Jay P McLaughlin
SRI-30827, a novel allosteric modulator of the dopamine transporter, alleviates HIV-1 Tat-induced potentiation of cocaine conditioned place preference in mice. NeuroImmune pharmacology and therapeutics 3 (1) (2023)

volume 2, number 1, 2023

Alice Kyungsun Min, Aislinn M Keane, Matthew Paltiel Weinstein, Talia H Swartz
The impact of cannabinoids on inflammasome signaling in HIV-1 infection. NeuroImmune pharmacology and therapeutics 2 (1) (2023)
Da Cheng, Zhenwu Luo, Sylvia Fitting, William Stoops, Sonya L Heath, Lishomwa C Ndhlovu, Wei Jiang
The link between chronic cocaine use, B cell perturbations, and blunted immune recovery in HIV-infected individuals on suppressive ART. NeuroImmune pharmacology and therapeutics 2 (1) (2023)
Huajun Liang, Thomas Ernst, Kenichi Oishi, Meghann C Ryan, Edward Herskovits, Eric Cunningham, Eleanor Wilson, Shyamasundaran Kottilil, Linda Chang
Abnormal brain diffusivity in participants with persistent neuropsychiatric symptoms after COVID-19. NeuroImmune pharmacology and therapeutics 2 (1) (2023)
Dominic Sales, Edward Lin, Victoria Stoffel, Shallyn Dickson, Zafar K Khan, Joris Beld, Pooja Jain
Apigenin improves cytotoxicity of antiretroviral drugs against HTLV-1 infected cells through the modulation of AhR signaling. NeuroImmune pharmacology and therapeutics 2 (1) (2023)

volume 2, number 2, 2023

Silvana Valdebenito, Akira Ono, Libin Rong, Eliseo A Eugenin
The role of tunneling nanotubes during early stages of HIV infection and reactivation: implications in HIV cure. NeuroImmune pharmacology and therapeutics 2 (2) (2023)
Sulie L Chang, Pankaj Seth, Jun Zhu, Gurudutt Pendyala, Jean M Bidlack, Santosh Kumar
The 27th Scientific Conference of the Society on NeuroImmune Pharmacology: New Delhi, India, March 15-18, 2023. NeuroImmune pharmacology and therapeutics 2 (2) (2023)
Natalie M Zahr, Edith V Sullivan, Adolf Pfefferbaum
Poor subjective sleep reported by people living with HIV is associated with impaired working memory. NeuroImmune pharmacology and therapeutics 2 (2) (2023)

volume 2, number 3, 2023

Sudipta Chakrabarti, Sukhamoy Gorai, Kalipada Pahan
A simple protocol for isolating microglia from adult mouse brain. NeuroImmune pharmacology and therapeutics 2 (3) (2023)
Stacey L Piotrowski, Allison Tucker, Steven Jacobson
The elusive role of herpesviruses in Alzheimer's disease: current evidence and future directions. NeuroImmune pharmacology and therapeutics 2 (3) (2023)
Ivy Antwi, Destiny Watkins, Alahn Pedawi, Atheel Ghrayeb, Christine Van de Vuurst, Theodore James Cory
Substances of abuse and their effect on SAR-CoV-2 pathogenesis. NeuroImmune pharmacology and therapeutics 2 (3) (2023)
Mai M Abdelmoaty, Pravin Yeapuri, Jatin Machhi, Yaman Lu, Krista L Namminga, Rana Kadry, Eugene Lu, Shaurav Bhattarai, Rodney Lee Mosley, Howard E Gendelman
Immune senescence in aged APP/PS1 mice. NeuroImmune pharmacology and therapeutics 2 (3) (2023)

volume 2, number 4, 2023

Trent A Bullock, Kalpani N Udeni Galpayage Dona, Jonathan F Hale, Paula Morales, Nadine Jagerovic, Allison M Andrews, Servio H Ramirez
Activation of CB2R by synthetic CB2R agonist, PM289, improves brain endothelial barrier properties, decreases inflammatory response and enhances endothelial repair. NeuroImmune pharmacology and therapeutics 2 (4) (2023)
Trent A Bullock, Kalpani N Udeni Galpayage Dona, Jonathan F Hale, Paula Morales, Nadine Jagerovic, Allison M Andrews, Servio H Ramirez
Activation of CB2R by synthetic CB2R agonist, PM289, improves brain endothelial barrier properties, decreases inflammatory response and enhances endothelial repair. NeuroImmune pharmacology and therapeutics 2 (4) (2023)
Trent A Bullock, Kalpani N Udeni Galpayage Dona, Jonathan F Hale, Paula Morales, Nadine Jagerovic, Allison M Andrews, Servio H Ramirez
Activation of CB2R by synthetic CB2R agonist, PM289, improves brain endothelial barrier properties, decreases inflammatory response and enhances endothelial repair. NeuroImmune pharmacology and therapeutics 2 (4) (2023)
Adrian Flores, Nghi M Nguyen, Gurudutt Pendyala
Developmental outcomes with perinatal exposure (DOPE) to prescription opioids. NeuroImmune pharmacology and therapeutics 2 (4) (2023)
Santosh Kumar, Namita Sinha, Sunitha Kodidela, Sandip Godse, Bhupesh Singla, Udai P Singh, Hari K Bhat
Resveratrol and its analogs suppress HIV replication, oxidative stress, and inflammation in macrophages. NeuroImmune pharmacology and therapeutics 2 (4) (2023)
Trent A Bullock, Kalpani N Udeni Galpayage Dona, Jonathan F Hale, Paula Morales, Nadine Jagerovic, Allison M Andrews, Servio H Ramirez
Activation of CB2R by synthetic CB2R agonist, PM289, improves brain endothelial barrier properties, decreases inflammatory response and enhances endothelial repair. NeuroImmune pharmacology and therapeutics 2 (4) (2023)
Pedro J Rodriguez Rivera, Huajun Liang, Amal Isaiah, Christine C Cloak, Miriam S Menken, Meghann C Ryan, Thomas Ernst, Linda Chang
Prenatal tobacco exposure on brain morphometry partially mediated poor cognitive performance in preadolescent children. NeuroImmune pharmacology and therapeutics 2 (4) (2023)
Wen Shi, Dengrong Jiang, Hannah Rando, Shivalika Khanduja, Zixuan Lin, Kaisha Hazel, George Pottanat, Ebony Jones, Cuimei Xu, Doris Lin, Sevil Yasar, Sung-Min Cho, Hanzhang Lu
Blood-brain barrier breakdown in COVID-19 ICU survivors: an MRI pilot study. NeuroImmune pharmacology and therapeutics 2 (4) (2023)

volume 2, number 1, 2022

Peter W Halcrow, Nirmal Kumar, Emily Hao, Nabab Khan, Olimpia Meucci, Jonathan D Geiger
Mu opioid receptor-mediated release of endolysosome iron increases levels of mitochondrial iron, reactive oxygen species, and cell death. NeuroImmune pharmacology and therapeutics 2 (1) (2022)
Courtney Veilleux, Eliseo A Eugenin
Mechanisms of Zika astrocyte infection and neuronal toxicity. NeuroImmune pharmacology and therapeutics 2 (1) (2022)
Yutong Liu, Gabriel C Gauthier, Howard E Gendelman, Aditya N Bade
Dual-Peak Lorentzian CEST MRI for antiretroviral drug brain distribution. NeuroImmune pharmacology and therapeutics 2 (1) (2022)

volume 2, number 2, 2022

Muhammad G Saleh, Linda Chang, Huajun Liang, Meghann C Ryan, Eric Cunningham, Jonathan Garner, Eleanor Wilson, Andrea R Levine, Shyamasundaran Kottilil, Thomas Ernst
Ongoing oxidative stress in individuals with post-acute sequelae of COVID-19. NeuroImmune pharmacology and therapeutics 2 (2) (2022)
Meghann C Ryan, Huajun Liang, Eleanor Wilson, Andrea Levine, Shyamasundaran Kottilil, Thomas Ernst, Linda Chang
Quantifying the Neuropsychiatric Symptoms in Post-Acute Sequelae of COVID-19 (PASC) using the NIH Toolbox ® and PROMIS. NeuroImmune pharmacology and therapeutics 2 (2) (2022)

volume 1, number 1, 2022

Suresh B Rangasamy, Debashis Dutta, Susanta Mondal, Moumita Majumder, Sridevi Dasarathy, Goutam Chandra, Kalipada Pahan
Protection of dopaminergic neurons in hemiparkinsonian monkeys by flavouring ingredient glyceryl tribenzoate. NeuroImmune pharmacology and therapeutics 1 (1) (2022)
Milica Markovic, Pravin Yeapuri, Krista L Namminga, Yaman Lu, Maamoon Saleh, Katherine E Olson, Howard E Gendelman, Rodney Lee Mosley
Interleukin-2 expands neuroprotective regulatory T cells in Parkinson's disease. NeuroImmune pharmacology and therapeutics 1 (1) (2022)
Milica Markovic, Pravin Yeapuri, Krista L Namminga, Yaman Lu, Maamoon Saleh, Katherine E Olson, Howard E Gendelman, Rodney Lee Mosley
Interleukin-2 expands neuroprotective regulatory T cells in Parkinson's disease. NeuroImmune pharmacology and therapeutics 1 (1) (2022)
Brandt Pence, Yufeng Zhang, Ivy Antwi, Theodore James Cory
Senescent macrophages alter fibroblast fibrogenesis in response to SARS-CoV-2 infection. NeuroImmune pharmacology and therapeutics 1 (1) (2022)
Nikhil K Kota, Michael Vigorito, Velu Krishnan, Sulie L Chang
Using IPA tools to characterize molecular pathways underlying the involvement of IRF7 in antiviral response to HIV. NeuroImmune pharmacology and therapeutics 1 (1) (2022)